No Data
No Data
Institutions Profited After Erasca, Inc.'s (NASDAQ:ERAS) Market Cap Rose US$169m Last Week but Retail Investors Profited the Most
Erasca Kicks off Phase III Trial for Naporafenib Combo Therapy in Melanoma
Express News | Erasca Inc - Favorable Mos and Mpfs Demonstrated in Pooled Analysis of Phase 1B and Phase 2 Trials in Nrasm Melanoma
Express News | Erasca Inc - Randomized Stage 1 Readout for Naporafenib Plus Trametinib Vs. Trametinib Monotherapy Expected in 2025
Express News | Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients With Nras-Mutant Melanoma
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients With NRAS-Mutant Melanoma
No Data